India is one of the world’s leading pharmaceutical producers, supplying affordable medicines to domestic and international markets. Yet, for millions of Indian families, buying medicines remains one of the most persistent household expenses. A prescription for diabetes, hypertension, heart disease or cancer can become a long-term financial commitment, particularly when treatment continues for years.
Medicines account for more than half of household out-of-pocket healthcare spending in India, according to research on healthcare expenditure. This means that even when patients can access a doctor or hospital, the cost of continuing treatment may still put pressure on their budgets. For families with limited incomes, the choice between purchasing medicines and meeting other essential expenses can become painfully difficult.
The challenge is not simply that some medicines are expensive. Wide differences in brand prices, distribution margins, gaps in public medicine supplies and limited awareness of lower-cost alternatives all contribute to the problem. Addressing these issues is essential to making healthcare more accessible and financially sustainable.
Why Do Medicines Cost More Than Expected?
One of the biggest concerns in India’s medicine market is the difference in prices between brands containing the same active pharmaceutical ingredient. Products with identical formulations can sometimes carry dramatically different price tags. Research published in Indian pharmaceutical journals has documented substantial price variation, including differences of several times between brands of the same medicine.
These gaps can reflect differences in marketing expenditure, brand positioning, distribution arrangements and commercial margins. However, a higher price does not automatically mean a medicine is more effective, just as a lower price alone does not establish its quality.
Patients often depend on their doctors’ prescriptions and may not know whether a suitable, less expensive alternative is available. When a particular brand becomes familiar, many people continue purchasing it without comparing prices.
For someone buying medicine occasionally, the difference may seem manageable. For a patient taking several medicines every day, the additional expense can accumulate over months and years. Improving access to reliable price information and encouraging discussions about treatment costs could help families make better-informed choices.
The Financial Burden of Long-Term Treatment
The cost of medicines becomes particularly difficult to manage when treatment is required throughout the year. Chronic conditions such as diabetes and hypertension need regular monitoring and consistent medication. Patients may also face additional expenses for laboratory tests, consultations, transport and dietary requirements.
India’s National Health Accounts for 2021–22 placed out-of-pocket expenditure at around 39.4% of total health expenditure, down from 48.8% in 2017–18. The decline suggests that public health spending and other financing arrangements have helped reduce the burden. However, direct payments by households remain a significant part of healthcare financing.
For families without adequate insurance or access to free public services, medicine bills can compete with spending on education, rent, food and savings. Some patients may delay refilling prescriptions, reduce doses without medical advice or postpone follow-up visits to manage immediate expenses.
These decisions can create a larger problem later. Poorly managed illnesses may lead to complications, hospitalisation and higher treatment costs. Making medicines affordable is therefore not only about reducing today’s bills; it can also help prevent avoidable health problems and financial distress in the future.
Retail Margins and the Question of Price Transparency
The final price of a medicine reflects several stages of the supply chain, including manufacturing, distribution, marketing, wholesale and retail sales. The size of these margins has become an important part of the debate over medicine affordability.
Concerns about exceptionally high trade margins on certain non-patented medicines and medical consumables have prompted calls for stronger government oversight. In October 2026, reported Supreme Court observations renewed attention to the need for more effective controls over medicine pricing.
The issue is particularly important when patients have little information about the relationship between a product’s manufacturing cost, trade margins and final retail price. Better transparency could help regulators identify excessive mark-ups and enable consumers to compare products more confidently.
At the same time, pricing policies must account for manufacturing costs, distribution expenses, product quality and the need to maintain a reliable supply. The goal should be to prevent unreasonable pricing without creating shortages or discouraging the availability of essential medicines.
Jan Aushadhi Kendras Offer an Affordable Alternative
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is among the government’s major initiatives to improve access to affordable medicines. Under the programme, Jan Aushadhi Kendras sell quality-assured generic medicines, generally at substantially lower prices than comparable branded products.
The network has expanded to more than 9,000 outlets nationwide, according to figures reported in recent programme updates. It provides an alternative for patients who want to reduce medicine expenses without abandoning prescribed treatment.
The potential savings can be significant for people managing chronic conditions. A lower monthly medicine bill can leave more money available for nutritious food, transport, children’s education and other household needs.
However, the benefits depend on availability, convenience and public confidence. Patients may struggle to find a nearby outlet or discover that a particular medicine is temporarily unavailable. Some also remain uncertain about generic medicines because they associate familiar brands with better quality.
Improving stock management, expanding access in underserved areas and providing clear information about quality standards could help more families benefit from the scheme.
How Government Price Controls Protect Patients
India regulates the prices of specified essential medicines through the National Pharmaceutical Pricing Authority (NPPA) under the Drug Price Control Order. Medicines included in the National List of Essential Medicines are subject to applicable price-control provisions.
These measures are designed to prevent prices of essential treatments from becoming unaffordable. The government has also introduced trade-margin controls for selected non-scheduled cancer medicines, aiming to improve access to high-cost treatments.
Yet, price regulation does not apply identically to every medicine. Some products fall under different regulatory categories, while others may face limited competition. As a result, patients can still encounter significant price differences even within the same therapeutic category.
A stronger approach could include regular reviews of essential medicine prices, better monitoring of trade margins, clear information for consumers and effective enforcement of existing rules. Authorities must also ensure that regulated medicines remain available in adequate quantities.
Price controls work best when they are supported by reliable distribution and meaningful competition rather than operating in isolation.
India’s Pharmaceutical Industry Can Help Bridge the Gap
India’s pharmaceutical manufacturing base offers an important opportunity to improve affordability. Generic medicines can provide lower-cost alternatives to established drugs, while biosimilars can broaden access to certain complex biological therapies.
The country is widely recognised as a major supplier of generic medicines globally. Its manufacturing capacity and established pharmaceutical supply chains can help expand access to treatments for chronic illnesses and other conditions, provided products meet the required quality standards.
However, producing affordable medicines is only one part of the solution. Patients must be able to obtain them consistently, doctors need confidence in their quality, and healthcare providers must be able to identify suitable alternatives.
Greater competition, efficient manufacturing and dependable distribution can help bring down costs. Strong regulatory oversight remains essential to ensure that affordability does not come at the expense of safety or effectiveness.
Public Hospitals Need Reliable Medicine Supplies
Public healthcare facilities can play a crucial role in reducing household expenses by supplying essential medicines free of charge or at low cost. But when medicines are unavailable, patients often have little choice but to purchase them from private pharmacies.
Such shortages can undermine the benefits of public healthcare, particularly for families who travel long distances to reach government hospitals. A patient may receive a consultation at little cost but still face a substantial bill for medicines that must be bought outside the facility.
Better procurement planning, digital inventory systems, timely replenishment and transparent monitoring can help hospitals maintain essential stocks. Authorities should also identify frequently unavailable medicines and address the causes of repeated shortages.
Reliable public supply would reduce direct spending by households while improving continuity of treatment.
Helping Patients Make Better-Informed Decisions
Patients should be encouraged to discuss the cost of prescribed medicines openly with their doctors. Asking whether a lower-priced generic equivalent is suitable can be a practical first step, particularly for long-term treatment.
Pharmacists can also help explain approved alternatives and available options. However, patients should not independently change dosages, stop treatment or substitute medicines without appropriate professional guidance. This is especially important for complex therapies and medicines that require careful monitoring.
Clearer prescription practices, accessible price comparisons and greater awareness of government-supported schemes can make medicine costs a more routine part of healthcare discussions.
The Road Ahead: Affordable Medicines Must Become a Priority
India’s pharmaceutical industry has established a strong position in global medicine production, but domestic affordability remains a major concern for many households. Reducing the financial burden will require coordinated action across pricing, manufacturing, public procurement and healthcare delivery.
Expanding Jan Aushadhi access, improving public hospital supplies, monitoring excessive margins and promoting quality-assured generic medicines could help families manage treatment costs more effectively. Better health coverage and stronger primary healthcare services would further reduce the risk of medical expenses pushing vulnerable households into financial difficulty.
Ultimately, affordable healthcare should not depend on a patient’s ability to identify a cheaper brand, travel between pharmacies or pay for medicines that are missing from a public hospital. Essential treatments need to be available, reliable and reasonably priced.
For India, the challenge is to ensure that the strength of its pharmaceutical industry translates into tangible benefits for ordinary families. When people can afford to follow their prescribed treatment without compromising other basic needs, the gains extend beyond better health to stronger household finances, improved productivity and a more inclusive economy.